| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Boldenone Cypionate targets the androgen receptor (AR), a nuclear receptor that mediates the effects of androgenic hormones. By binding to and activating the AR, boldenone cypionate stimulates the transcription of androgen-responsive genes, leading to increased protein synthesis, nitrogen retention, and muscle growth. The compound's anabolic effects are mediated through the activation of the AR in skeletal muscle and other tissues, while its androgenic effects (e.g., virilization, prostate growth) are mediated through the activation of the AR in androgen-sensitive tissues. Boldenone has a relatively low androgenic to anabolic ratio compared to testosterone, meaning that it has more anabolic effects and fewer androgenic side effects. The cypionate ester does not affect the compound's binding to the AR but influences its pharmacokinetics by providing a sustained release of boldenone from the injection site. Boldenone cypionate also exhibits aromatase activity (conversion to estradiol) to a lesser extent than testosterone, which may influence its side effect profile.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that boldenone cypionate is a potent agonist of the androgen receptor. In AR-dependent cell lines (e.g., LNCaP prostate cancer cells, C2C12 myoblasts), boldenone treatment at concentrations of 0.1-10 µM stimulates the expression of androgen-responsive genes, including PSA and myogenin, and promotes cell proliferation and differentiation. The compound's anabolic effects have been confirmed in myotube cultures, where it stimulates protein synthesis and myotube hypertrophy. Boldenone also has been shown to have anti-catabolic effects, reducing the degradation of muscle proteins. In addition to its effects on muscle cells, boldenone has been shown to influence bone metabolism, promoting osteoblast proliferation and differentiation. The compound's effects on lipid metabolism have also been investigated, with boldenone reducing adipogenesis and promoting lipolysis in adipocyte cultures. In cell viability assays, boldenone cypionate does not exhibit significant cytotoxicity at concentrations up to 100 µM, indicating a favorable safety profile for in vitro applications.
|
| ln Vivo |
In vivo studies have demonstrated the anabolic effects of boldenone cypionate in animal models. In rats and mice, intramuscular or subcutaneous administration of boldenone cypionate at doses of 1-10 mg/kg/week increases muscle mass, strength, and bone density. The compound's effects are dose-dependent and are mediated through the activation of the androgen receptor. In veterinary medicine, boldenone cypionate is used to promote muscle growth in horses and other livestock. In addition to its anabolic effects, boldenone cypionate has been shown to improve recovery from injury and to have immunomodulatory effects. However, the compound's use is associated with significant side effects, including virilization, hepatotoxicity, cardiovascular effects, and suppression of the hypothalamic-pituitary-gonadal axis. Boldenone cypionate is a controlled substance and is not approved for human use in most countries.
|
| Enzyme Assay |
For in vitro cell-based assays, boldenone cypionate is typically evaluated for its effects on AR activation, cell proliferation, and protein synthesis in muscle and prostate cell lines. Cells (e.g., LNCaP, C2C12) are seeded in 6- or 12-well plates and treated with the compound at concentrations of 0.01-100 µM for 24-72 hours. AR activation is assessed by measuring the expression of androgen-responsive genes (PSA, FKBP5, myogenin) by qPCR or by using an AR-dependent reporter gene assay. Cell proliferation is measured using MTT or BrdU incorporation assays. Protein synthesis is measured by the incorporation of radiolabeled amino acids or by assessing myotube diameter and protein content. For cytotoxicity assays, cells are treated with the compound, and cell viability is determined using MTT or LDH release assays. All experiments include appropriate positive and negative controls (e.g., dihydrotestosterone, testosterone), and results are expressed as mean ± standard deviation from at least three independent experiments.
|
| Animal Protocol |
For in vivo animal experiments, boldenone cypionate is typically administered intramuscularly to rodents or other animals. For anabolic studies, animals (e.g., rats, mice) are treated with the compound at doses of 1-10 mg/kg/week for 4-8 weeks. Muscle mass (e.g., gastrocnemius, soleus, quadriceps) is measured at the end of the study, and muscle strength is assessed using grip strength tests or treadmill performance. Bone density is measured using DEXA or micro-CT. For pharmacokinetic studies, blood samples are collected at various time points, and plasma concentrations of boldenone are measured by LC-MS/MS. For toxicology studies, animals are treated with the compound for 4-12 weeks, and parameters such as body weight, organ weights, hematology, serum biochemistry (including liver function tests and lipid profiles), and histopathology (particularly of the liver, prostate, and testes) are assessed. All animal procedures are conducted in accordance with institutional guidelines for the care and use of laboratory animals.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for boldenone cypionate indicate that it is a long-acting ester that provides a sustained release of boldenone. The compound has a molecular weight of 410.59 g/mol and a molecular formula of C₂₇H₃₈O₃. Following intramuscular injection, boldenone cypionate is slowly absorbed from the injection site, with a Tmax of several days and a half-life of 2-3 weeks. The compound is metabolized in the liver and excreted in urine and feces. The compound is stable when stored as a powder at room temperature, protected from light and moisture. For in vivo administration, boldenone cypionate can be formulated in a suitable oil vehicle (e.g., sesame oil, cottonseed oil) for intramuscular injection.
|
| Toxicity/Toxicokinetics |
Boldenone cypionate has significant toxicity, particularly when used at high doses or for prolonged periods. The compound is hepatotoxic, causing liver enzyme elevations and, in rare cases, liver tumors. Boldenone cypionate also suppresses the hypothalamic-pituitary-gonadal axis, leading to decreased endogenous testosterone production, testicular atrophy, and infertility. The compound's androgenic effects can cause virilization in women, including hirsutism, voice deepening, and clitoral enlargement. In men, boldenone cypionate can cause gynecomastia, acne, and male pattern baldness. The compound also has cardiovascular effects, including increased LDL cholesterol, decreased HDL cholesterol, and increased risk of cardiovascular events. As with all anabolic steroids, boldenone cypionate is a controlled substance in many countries and is not approved for human use. The compound is for research use only and is not intended for human therapeutic use.
|
| Additional Infomation |
Boldenone Cypionate is a research-use only compound and has not been approved for human clinical applications. It is also known as boldenone cyclopentanepropionate. The compound has a molecular formula of C₂₇H₃₈O₃ and a molecular weight of 410.59 g/mol. Boldenone Cypionate is a synthetic anabolic-androgenic steroid that is a derivative of testosterone, originally developed for veterinary use. The compound is used in research to study the effects of anabolic steroids on muscle growth, bone density, and metabolism. Boldenone Cypionate is available from various research chemical suppliers with purities typically ≥95% (HPLC). Storage recommendations include keeping the compound in a tightly sealed container, protected from light and moisture, at room temperature.
|
| Molecular Formula |
C27H38O3
|
|---|---|
| Molecular Weight |
410.58882
|
| Exact Mass |
410.282
|
| CAS # |
106505-90-2
|
| PubChem CID |
71314193
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
527.3±50.0 °C at 760 mmHg
|
| Flash Point |
225.0±30.2 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.558
|
| LogP |
6.95
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
30
|
| Complexity |
773
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@@]12C=CC(=O)C=C2CC[C@H]3[C@@H]4CC[C@@H]([C@@]4(C)CC[C@@H]31)OC(=O)CCC5CCCC5
|
| InChi Key |
QPMSXPMLTYTHGM-ZLQWOROUSA-N
|
| InChi Code |
InChI=1S/C27H38O3/c1-26-15-13-20(28)17-19(26)8-9-21-22-10-11-24(27(22,2)16-14-23(21)26)30-25(29)12-7-18-5-3-4-6-18/h13,15,17-18,21-24H,3-12,14,16H2,1-2H3/t21-,22-,23-,24-,26-,27-/m0/s1
|
| Chemical Name |
[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4355 mL | 12.1776 mL | 24.3552 mL | |
| 5 mM | 0.4871 mL | 2.4355 mL | 4.8710 mL | |
| 10 mM | 0.2436 mL | 1.2178 mL | 2.4355 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
